Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Submitted by
admin
on May 31, 2009 - 9:58am
Source:
Yahoo/Globa News Wire
News Tags:
Sanofi
breast cancer
Headline:
Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients With Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival
Do Not Allow Advertisers to Use My Personal information
